Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408428 | 0.93 | S1PR1 (0.67) | S1PR1S1PR3NR1H4EDNRBEDNRA | |
| SCHEMBL2805509 | 0.88 | S1PR1 (0.64) | S1PR1S1PR3NR1H4HAVCR2 | |
| SCHEMBL410689 | 0.86 | S1PR1 (0.66) | S1PR1S1PR3NR1H4HAVCR2 | |
| SCHEMBL410355 | 0.86 | S1PR1 (0.75) | S1PR1S1PR3NR1H4 | |
| SCHEMBL9968863 | 0.85 | S1PR1 (0.68) | S1PR1S1PR3NR1H4HAVCR2 | |
| SCHEMBL13146062 | 0.84 | S1PR1 (0.65) | S1PR1S1PR3NR1H4HAVCR2 | |
| SCHEMBL409330 | 0.84 | S1PR1 (0.60) | S1PR1S1PR3NR1H4HAVCR2 | |
| SCHEMBL2775225 | 0.83 | S1PR1 (0.69) | S1PR1S1PR3NR1H4 | |
| SCHEMBL2807537 | 0.83 | S1PR1 (0.71) | S1PR1S1PR3 | |
| SCHEMBL2805596 | 0.83 | S1PR1 (0.63) | S1PR1S1PR3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | S1PR1 448/4885S1PR3 310/4885NR1H4 923/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | S1PR1 448/4885S1PR3 310/4885NR1H4 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.